Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period-Reference-Cited by-同舟云学术

Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period

Published:2018-03-20 Issue:6 Volume:34 Page:981-994
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Seino Yutaka¹²,Sasaki Takashi³,Fukatsu Atsushi⁴,Imazeki Hisae⁵,Ochiai Hidekazu⁵,Sakai Soichi⁵

Affiliation:

1. Kansai Electric Power Hospital, Osaka, Japan;

2. Kansai Electric Power Medical Research Institute, Kobe, Japan;

3. Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Chiba, Japan;

4. Yachiyo Hospital, Aichi, Japan;

5. Taisho Pharmaceutical Co. Ltd., Tokyo, Japan

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1441816

Reference25 articles.

1. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

2. Evidence-based practice guideline for the treatment for diabetes in Japan 2013

3. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

4. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

5. Toward Defining a Cutoff Score for Elevated Fear of Hypoglycemia on the Hypoglycemia Fear Survey Worry Subscale in Patients With Type 2 Diabetes

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus;Journal of Pharmaceutical Health Care and Sciences;2023-09-15

2. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

3. Renal, cardiovascular, and safety outcomes of adding sodium–glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis;International Urology and Nephrology;2023-07-29

4. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial;BMJ Open Diabetes Research & Care;2023-06

5. Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-03